According to a new market report published by Lucintel, the future of the nuclear medicine/radiopharmaceutical market looks promising with opportunities in the hospitals, diagnostic centers, and research institutes. The global nuclear medicine/radiopharmaceutical market is expected to grow with a CAGR of 9% from 2019 to 2024. The major drivers for this market are increasing incidence and prevalence of cancer and cardiovascular diseases (CVD) and growing investment through public private partnerships to modernize diagnostic imaging centers, alpha radioimmunotherapy (RIT) based targeted cancer treatment, and advances in radiotracers.
In this market, diagnostic nuclear medicine/radiopharmaceutical and therapeutic nuclear medicine/radiopharmaceutical are the major product segments. Cardiology, lymphoma, thyroid, oncology, neurology, bone metastasis, and endocrine tumors are the major applications of the global nuclear medicine/radiopharmaceutical market.
North America will remain the largest market over the forecast period due to the development of novel technologies for radioisotope production and government funding.
Cardinal Health, Mallinckrodt, GE Healthcare, Lantheus Medical Imaging, Bayer, Bracco Imaging, Eczacibasi-Monrol Nuclear Products, Noridian, and Iba Molecular are among the major manufacturers of nuclear medicine/radiopharmaceutical market.
Lucintel, a leading global strategic consulting and market research firm, has analyzed growth opportunities in the global nuclear medicine/radiopharmaceutical market by product type, application, end user, and region. Lucintel has prepared comprehensive research report entitled "Global Nuclear Medicine/Radiopharmaceutical Market 2019-2024: Trends, Forecast, and Opportunity Analysis". This Lucintel report serves as a catalyst for growth strategy as it provides comprehensive data and analysis on trends, key drivers, and directions. The study includes a forecast for the global nuclear medicine/radiopharmaceutical market by product type, application, end use, and region as follows:
By Product Type [$M shipment analysis for 2013 – 2024]:
Diagnostic Nuclear Medicine/Radiopharmaceutical
SPECT Radiopharmaceutical
PET Radiopharmaceutical
Therapeutic Nuclear Medicine/Radiopharmaceutical
Beta Emitters
Alpha Emitters
Brachytherapy
By Application [$M shipment analysis for 2013 – 2024]:
Cardiology
Lymphoma
Thyroid
Neurology
Oncology
Bone Metastasis
Endocrine Tumors
By End Use [$M shipment analysis for 2013 – 2024]:
Hospitals and Diagnostic Centers
Research Institutes
By Region [$M shipment analysis for 2013 – 2024]:
United States
Canada
Mexico
United kingdom
Germany
France
Italy
Spain
This research report of more than 150 pages will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link…… or helpdesk@lucintel.com.
About Lucintel
Lucintel, the premier global Management Consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, Growth Consulting, M&A, and Due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.